Pittenger & Anderson Inc. Has $14.36 Million Stock Position in Johnson & Johnson $JNJ

Pittenger & Anderson Inc. raised its holdings in shares of Johnson & Johnson (NYSE:JNJFree Report) by 9.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 93,995 shares of the company’s stock after acquiring an additional 7,756 shares during the quarter. Pittenger & Anderson Inc.’s holdings in Johnson & Johnson were worth $14,358,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in JNJ. Brighton Jones LLC grew its stake in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Wealth Group Ltd. bought a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $218,000. GAMMA Investing LLC grew its stake in shares of Johnson & Johnson by 48.0% during the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock worth $7,215,000 after acquiring an additional 14,118 shares in the last quarter. Center for Financial Planning Inc. grew its stake in shares of Johnson & Johnson by 0.7% during the 1st quarter. Center for Financial Planning Inc. now owns 14,710 shares of the company’s stock worth $2,440,000 after acquiring an additional 107 shares in the last quarter. Finally, LVZ Inc. bought a new position in shares of Johnson & Johnson in the first quarter valued at $214,000. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.9%

JNJ stock opened at $191.93 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a fifty day moving average price of $181.27 and a two-hundred day moving average price of $165.37. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The stock has a market cap of $462.23 billion, a price-to-earnings ratio of 18.53, a price-to-earnings-growth ratio of 2.28 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The firm had revenue of $24.02 billion during the quarter. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on JNJ shares. Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday. HSBC raised their target price on shares of Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. Raymond James Financial raised their target price on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Argus set a $210.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Finally, Sanford C. Bernstein raised their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research note on Monday, October 6th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $200.06.

Check Out Our Latest Research Report on Johnson & Johnson

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.